MedPath

The Clinical Significance of Portal Hypertension After Cardiac Surgery: a Multicenter Prospective Observational Study

Completed
Conditions
Congestive Heart Failure
Venous Congestion
Surgery--Complications
Right Heart Failure
Anesthesia
Interventions
Diagnostic Test: Doppler assessment of portal vein flow
Registration Number
NCT03656263
Lead Sponsor
Montreal Heart Institute
Brief Summary

Portal flow pulsatility detected by Doppler ultrasound is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse outcomes based on previous studies performed at the Montreal Heart Institute. This multicenter prospective cohort study aims to determine if portal flow pulsatility after cardiopulmonary bypass separation is associated with a longer requirement of life support after cardiac surgery.

Detailed Description

Hypothesis: Portal flow pulsatility detected by Doppler ultrasound during cardiac surgery is an echographic marker of cardiogenic portal hypertension from right ventricular failure and is associated with adverse clinical outcomes.

Background: Peri-operative right ventricular failure is associated with a high mortality rate. In this context, organ perfusion is hampered by both the reduction of cardiac output and venous congestion from the elevation of central venous pressure. The clinician's objective is to appreciate the hemodynamic impact on end-organs in an effort to adjust the therapy accordingly since the ultimate goal is to optimize their perfusion. Based on this rationale, organ specific blood flow assessment using Doppler ultrasound could be used to personalize management. In order to non-invasively assess the presence of cardiogenic portal hypertension, Doppler ultrasound can be used to detect portal flow pulsatility, an abnormal variation in the velocity of blood flow within the main portal vein. In two single-center cohort studies, the presence of portal flow pulsatility after cardiac surgery was independently associated with post-operative complications such as major bleeding, acute kidney injury (AKI) and delirium as well as increased length of intensive care unit (ICU) stay.

Specific Objectives: This multi-center cohort study aim to determine whether the association between portal flow pulsatility and organ dysfunction seen in previous studies is present across multiple cardiac surgery centers.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
360
Inclusion Criteria
  • Adult patients (≥18 years old) and able to give informed consent undergoing cardiac surgery with the use of CPB for whom peri-operative TEE is planned.

  • High surgical risk defined as at least one of the following:

    1. Multiple surgical procedures planned
    2. EuroSCORE II ≥ 5%
    3. Known pulmonary hypertension (mPAP>25mmHg or sPAP>40mmHg).
Exclusion Criteria
  • Patient with a critical pre-operative state defined as vasopressor requirement, mechanical circulatory support, dialysis, mechanical ventilation or cardiac arrest necessitating resuscitation.
  • Patient with known condition that could interfere with portal flow assessment or interpretation (liver cirrhosis, portal vein thrombosis)
  • Planned cardiac transplantation
  • Planned ventricular assist device implantation

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
High risk cardiac surgery patientsDoppler assessment of portal vein flowDefined as either: * Multiple surgical procedures planned and/or, * EuroSCORE ≥ 5% and/or, * Known pulmonary hypertension (mPAP\>25 mmHg or sPAP \> 40 mmHg)
Primary Outcome Measures
NameTimeMethod
Duration of invasive life support after cardiac surgery. (Tpod)Up to 28 days

Defined as the time of Persistent Organ Dysfunction (POD) or Death

Secondary Outcome Measures
NameTimeMethod
Deep sternal wound infection or mediastinitisUp to 28 days

Diagnosis of a deep incisional surgical site infection or mediastinitis by a surgeon or attending physician.

DeliriumUp to 28 days

Defined as a intensive care delirium screening checklist (ICDSC) score of ≥4 in the week following surgery or positive result for the Confusion Assessment Method for the ICU (CAM-ICU)

Total duration of ICU stay in hoursUp to 28 days

Number of hours passed in the ICU

Duration of hospital stay (in days)Up to 28 days

Number of days hospitalized from the day of surgery to discharge

All cause deathUp to 28 days

Death from any cause

Surgical reintervention for any reasonsUp to 28 days

Re-operation after the initial surgery for any cause

Major bleeding defined by the Bleeding Academic Research Consortium (BARC)Up to 28 days

Perioperative intracranial bleeding within 48h Reoperation after closure of sternotomy for the purpose of controlling bleeding Transfusion of ≥5 units of whole blood of packed red blood cells within a 48 hours period Chest tube output ≥2L within a 24 hours period

StrokeUp to 28 days

A central neurologic deficit persisting longer than 72 hours

Duration of mechanical ventilation (in hours)Up to 28 days

Number of hours of mechanical ventilation

Acute kidney injury according to KDIGO serum creatinine criteriaUp to 28 days

Stage 1: ≥50% or 27 umol/L increases in serum creatinine Stage 2: ≥100% increase in serum creatinine Stage 3 ≥200% increase in serum creatinine or an increase to a level of ≥254 umol/L or dialysis initiation.

A composite outcome of major morbidity or mortality (41): including death, prolonged ventilation, stroke, renal failure (Stage ≥2), deep sternal wound infection and reoperation for any reason.Up to 28 days

Composite endpoint after cardiac proposed by the Society of Thoracic Surgeons

Trial Locations

Locations (1)

Montreal Heart Institute

🇨🇦

Montreal, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath